UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 8, 2004 PHARMAFRONTIERS CORP. --------------------- (Exact name of registrant as specified in its charter) TEXAS ----- (State or other jurisdiction of incorporation) 000-25513 760333165 --------- --------- (Commission File Number) (I.R.S. Employer Identification No.) 18205 Burkhardt Rd., Tomball Texas, 77377 ----------------------------------------- (Address of principal executive offices, including zip code) (281) 290-6655 -------------- (Registrant's telephone number, including area code) ITEM 8.01. OTHER EVENTS. On November 8, 2004, PharmaFrontiers Corp. issued a press release announcing the closing of its previously announced acquisition of Opexa Pharmaceuticals, Inc., a Houston-based developer of cell-based therapeutics for autoimmune diseases, initially targeting multiple sclerosis. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBIT (c) Exhibits The following exhibits are to be filed as part of this 8-K: EXHIBIT NO. IDENTIFICATION OF EXHIBIT ----------- ------------------------- 99.1 Press Release of PharmaFrontiers Corp. dated November 8, 2004. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHARMAFRONTIERS CORP. By: /s/ David McWilliams ------------------------- David McWilliams, Chief Executive Officer DATE: November 8, 2004 EXHIBIT INDEX Exhibit No. Description - ----------- ----------- 99.1 Press Release of PharmaFrontiers Corp. dated November 8, 2004